Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety

This study is testing whether adding an immunotherapy drug called adebelimab to a chemotherapy combination (irinotecan liposomal, oxaliplatin, fluorouracil, and leucovorin) works well as a first-line treatment for pancreatic cancer that has spread to the liver. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with pancreatic cancer with liver metastases (confirmed by biopsy) - You have not received any prior systemic cancer treatment - Your overall health is good (ECOG 0–1) - Your major organs are functioning adequately - Your estimated survival is at least 12 weeks **You may NOT be eligible if...** - Your cancer has spread to the brain - You have received prior chemotherapy or targeted therapy - You had adjuvant therapy within the last 6 months - You have serious organ problems that make treatment unsafe Talk to your doctor to see if this trial is right for you.